Skip to main content

Table 1 Clinicopathologic features of the whole

From: Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

Characteristics

Whole series

Luminal class

HER2+ class

Triple-negative class

  

Training

No (%)

Validation

No (%)

P

Training

No (%)

Validation

No (%)

P

Training

No (%)

Validation

No (%)

P

Age

          

Median (Range)

54 (18-70)

55 (18-70)

55 (28-70)

0.690

52 (29-69)

52 (27-70)

0.657

49.5 (29-70)

50 (27-70)

0.885

Menopausal status

          

Premenopausal

571 (39.2)

116 (36.7)

232 (35.6)

0.887

31 (47.7)

58 (45.3)

 

44 (54.8)

90 (56.3)

0.892

Postmenopausal

886 (60.8)

200 (63.3)

419 (64.4)

 

34 (52.3)

70 (57.7)

0.762

36 (45.1)

70 (34.8)

 

Tumor grade

          

Grade I

255 (17.5)

80 (25.3)

151 (23.2)

 

2 (3.1)

5 (3.9)

 

3 (3.6)

1 (0.6)

0.892

Grade II

479 (32.9)

141 (43.9)

282 (43.3)

0.371

8 (12.3)

25 (19.5)

0.417

7 (8.3)

8 (5.0)

 

Grade III

723 (48.6)

95 (29.6)

218 (33.5)

 

55 (84.6)

98 (76.6)

 

70 (88.1)

151 (94.4)

 

Tumor size

          

   ≤ 2 cm

899 (61.8)

215 (68.1)

433 (66.5)

0.561

40 (61.5)

77 (60.2)

0.877

42 (52.5)

71 (44.4)

0.180

   > 2 cm

556 (38.2)

101 (31.9)

218 (33.5)

 

25 (38.5)

51 (39.8)

 

38 (47.5)

89 (55.6)

 

Tumor type

          

Ductal, no special type

853 (58.5)

159 (50.3)

331 (50.8)

0.874

59 (90.8)

112 (88.2)

0.807

70 (87.5)

136 (86.1)

1.00

Other histologic types

604 (41.5)

157 (49.7)

320 (49.2)

 

6 (9.2)

15 (11.8)

 

12 (12.5)

22 (13.9)

 

NPI a

          

Good

457 (31.4)

141 (44.6)

275 (42.2)

 

4 (6.5)

16 (12.5)

 

7 (8.6)

13 (8.1)

 

Moderate

767 (52.6)

145 (45.9)

295 (45.3)

0.312

47 (72.3)

78 (60.9)

0.226

55 (68.9)

109 (68.1)

0.417

Poor

233 (16.0)

30 (9.5)

81 (12.4)

 

14 (21.5)

34 (26.6)

 

18 (22.5)

38 (23.8)

 

Mean (range)

3.4 (2.04-5)

3.42 (2.05-5)

3.43 (2.06-5)

 

4.7 (2.6-5)

4.7 (2.6-5)

 

4.51 (2.05-5)

4.52 (2.05-5)

 

Recurrence

          

Local: No

1,249 (89.0)

283 (89.6)

588 (90.3)

 

55 (84.6)

108 (84.4)

 

70 (87.5)

136 (85.0)

0.564

   Yes

160 (11.0)

33 (10.4)

63 (9.7)

0.819

10 (15.4)

20 (15.6)

1.000

10 (12.5)

24 (15.0)

 

Regional: No

1,280 (91.0)

291 (92.1)

594 (91.2)

 

58 (89.2)

112 (87.5)

 

70 (87.5)

147 (91.9)

0.259

   Yes

129 (9.0)

25 (7.9)

57 (8.8)

0.713

7 (10.8)

16 (12.5)

0.817

10 (12.5)

13 (8.1)

 

Distant: No

1,014 (69.6)

239 (75.6)

473 (72.7)

0.278

34 (52.3)

71 (55.5)

 

50 (62.5)

107 (66.9)

0.573

   Yes

443 (30.4)

77 (24.4)

178 (27.3)

 

31 (47.7)

57 (44.5)

0.760

30 (37.5)

53 (33.1)

 
  1. aSeries (n = 1,457), training sets, and validation sets of luminal, HER2+ (n = 193), and TN (n = 244) molecular BC classes Nottingham Prognostic Index. Good Prognostic Group, ≤ 3.4; Moderate Prognostic Group, 3.41 to 5.4, Poor Prognostic Group, > 5.4